BetterInvesting Magazine Update on Stride Inc.  and Amgen Inc.

BetterInvesting Magazine Update on Stride Inc. and Amgen Inc.

Stride Inc.'s recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine considers Stride Inc. (NYSE:LRN) as worthy of further study and has named the company its "Stock to Study" for the August 2025 issue for investors' informational and educational use.

The fundamental data is eye-opening; investors can view Stride's sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors Corp., here .

A full report on Stride will appear in the August 2025 issue of BetterInvesting Magazine.

The same issue of BetterInvesting Magazine will also include a fundamental review of Amgen Inc. (NASDAQ:AMGN), which the independent Editorial Advisory and Securities Review Committee believes is worthy of further study from an undervalued perspective.

Committee members are Daniel J. Boyle , CFA; Marisa Bradbury , CFA; Philip Keating , CFA; Walter J. Kirchberger , CFA; Anne Nichols , CFA; and Dan Rutter , CFA.

Doron P. Levin , an editor of the magazine, serves as the committee's chairperson.

Securities mentioned are for study and presented for educational purposes only. They are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting. Investors should conduct their own review and analysis of any company of interest using the Stock Selection Guide before making an investment decision.

About BetterInvesting:

BetterInvesting™, a national 501(c)(3) nonprofit, investment education organization, has been empowering everyday Americans since 1951. Also known as the National Association of Investors™ (NAIC®), we have helped more than 5 million people from all walks of life learn how to improve their financial future. BetterInvesting provides unbiased, in-depth investing education and powerful online stock analysis tools to create successful lifelong investors. BetterInvesting staff, along with a dedicated community of volunteers across America, teach the organization's principles and time-tested methodology to individuals and investment clubs. For more information about BetterInvesting, please visit www.betterinvesting.org

Follow us on LinkedIn , Instagram and Facebook .

Contact: 877-275-6242

Cision View original content: https://www.prnewswire.com/news-releases/betterinvesting-magazine-update-on-stride-inc-nyse-lrn-and-amgen-inc-nasdaq-amgn-302466516.html

SOURCE NAIC-BetterInvesting

News Provided by PR Newswire via QuoteMedia

AMGN:US
The Conversation (0)
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.

Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.

(TheNewswire) Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECH™ Kelowna, British Columbia - June 9, 2026 TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery... Keep Reading...
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway

Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway

Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECH™ KELOWNA, BC / ACCESS Newswire / June 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that dosing... Keep Reading...
Doctor holds tablet displaying digital human body with health data, overlaid with medical icons.

Immunotherapy Innovations: Increasing Survival in Metastatic Breast Cancer

Metastatic breast cancer (MBC) remains incurable, with approximately only one-third of diagnosed women meeting the five year survival rate.Subtypes like triple-negative breast cancer (TNBC) or heavily pretreated hormone receptor-positive disease often come with more treatment challenges, leading... Keep Reading...
Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program

Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program

KELOWNA, BC / ACCESS Newswire / June 3, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it is attending the BIO International Convention ("BIO") from June 22-25 in San Diego, CA. Lexaria's attendance... Keep Reading...
Collage with hands holding shiny DNA molecule on blue background.

5 Biggest Biotechnology ETFs in 2026

The biotech sector has made significant strides in recent years, and the market's volatility can increase the appeal of biotech ETFs. Even with a good understanding of the system, no one can predict which treatment, device or therapy will give the biggest return, making biotech exchange-traded... Keep Reading...
Doctor holding stethoscope over digital document interface

Beyond the Lab: Top-Tier Clinical Validation in Biotech Investing

Nature Medicine’s “Eleven Clinical Trials That Will Shape Medicine in 2026” highlights studies poised to influence patient care. Among the oncology selections, BriaCell Therapeutics' (TSX:BCT,NASDAQ:BCTX) pivotal Phase 3 trial of Bria-IMT™ stands out as a rare entry. This feature underscores the... Keep Reading...

Interactive Chart

Latest Press Releases

Related News